The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Chengdu, People’s Republic of China
Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
Sichuan University, Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Chengdu, People’s Republic of China
Sichuan University, Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Chengdu, People’s Republic of China